ClinicalTrials.gg
CompletedNCT03624127POETYK-PSO-1Updated Jan 30, 2023Results posted

Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis

A Phase 3 interventional study of BMS-986165 and Placebo in Psoriasis, sponsored by Bristol-Myers Squibb. Completed at 165 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-30.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
666
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing deucravacitinib in Psoriasis — 6 open to participants now, 6 under way, 4 of them phase 3. deucravacitinib · Psoriasis.

Enrollment
5th of 26
666 · median 102
Started
2018
with 2 others
Phase 3
9 of 26
4 open now
Registered
7th of 26
by date
Lead sponsor
18 of 26
Bristol-Myers Squibb

Among the 26 studies testing deucravacitinib in Psoriasis, this one is the 5th largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 3, and was the 7th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 26 studies testing deucravacitinib in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About deucravacitinib

deucravacitinib: first FDA approval 2022 (SOTYKTU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing deucravacitinib in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Plaque psoriasis for at least 6 months
  • Moderate to severe disease
  • Candidate for phototherapy or systemic therapy

Exclusion criteria

Exclusion Criteria:

  • Other forms of psoriasis
  • History of recent infection
  • Prior exposure to BMS-986165 or active comparator

Other protocol defined inclusion/exclusion criteria apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
666 participants (actual)

Study arms

  • Experimental
    BMS-986165

    Drug: BMS-986165

  • Placebo comparator
    Placebo

    Other: Placebo

  • Active comparator
    Apremilast

    Drug: Apremilast

Interventions

  • Specified dose on specified days

  • OtherPlacebo

    Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1)

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; Severe = 4). sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 or 1 with at least 2-point improvement from baseline using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason.

    Time frame: Week 16

  2. The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 75)

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

    Time frame: Baseline and Week 16

Secondary outcomes

  1. The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score at Week 16 (PASI 90)

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the response as a number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

    Time frame: Baseline and Week 16

  2. The Number of Participants Who Achieve a 100% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 100)

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the response as a number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

    Time frame: Baseline and Week 16

  3. The Number of Participants With a Static Physician's Global Assessment Score of 0 at Week 16 (sPGA 0)

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). sPGA 0 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason.

    Time frame: Week 16

  4. Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16

    PSSD is an 11-item participant-reported instrument that assesses severity of symptoms and participant-observed signs commonly associated in plaque psoriasis. PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participants-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding) using 0-10 numerical ratings. The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). A symptom score will be derived by averaging the 5 questions and multiplying by 10. A sign score will be derived by averaging the 6 questions and multiplying by 10. A total PSSD score with range 0-100 will be derived from taking the average of the symptom and sign scores, where 0 representing the least severe symptom/sign and 100 the most severe. A mBOCF approach will be used for missing data. Baseline is defined as the measurement at the randomization visit (Week 0).

    Time frame: Baseline and Week 16

  5. Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score 0 at Week 16

    PSSD with a 24-hour recall period is an 11-item participant-reported instrument that assesses severity of symptoms and participant-observed signs commonly associated in plaque psoriasis. PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participants-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding) using 0-10 numerical ratings. The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). PSSD 0 is the response as a number of participants who experience a PSSD symptom score that is derived from the average of the scores and determines psoriasis severity as 0 among participants with a baseline PSSD symptom score \>= 1.

    Time frame: Week 16

  6. The Number of Participants With a Dermatology Life Quality Index (DLQI) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (DLQI 0/1)

    DLQI is a participant-reported quality of life index which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week before questionnaire. Each question is scored on a scale of 0 to 3 by a tick box (0 = "not at all"; 1 = "a little"; 2 = "a lot"; or 3 = "very much"). The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment). DLQI 0/1 is the response as a number of participants who experience DLQI score of 0 or 1 among participants with a baseline DLQI score \>=2.

    Time frame: Week 16

  7. Number of Participants With a Physician's Global Assessment-Fingernails (PGA-F) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16

    PGA-F overall condition of the fingernails is rated on a 5-point scale (0 = clear; 1 = minimal; 2 = mild; 3 = moderate; and 4 = severe). PGA-F 0/1 is the response as a number of participants with a PGA-F score of 0 or 1 with at least a 2-point improvement from baseline among participants with a baseline PGA-F score \>=3.

    Time frame: Week 16

  8. The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (PASI 75)

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

    Time frame: Baseline and Week 16

  9. The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (sPGA 0/1)

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; Severe = 4). sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 or 1 with at least 2-point improvement from baseline using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason.

    Time frame: Week 16

  10. The Number of Participants With a Scalp Specific Physician's Global Assessment (Ss-PGA) Score 0 or 1 at Week 16 (Ss-PGA 0/1)

    ss-PGA is a 5-point scale that evaluates scalp lesions in terms of clinical signs of redness, thickness, and scaliness. The higher ss-PGA score denotes to more severe disease activity (0 = absence of disease; 1 = very mild disease; 2 = mild disease; 3 = moderate disease; 4 = severe disease). ss-PGA 0/1 is the response as a number of participants who experience a ss-PGA score that determines scalp lesions severity as 0 or 1 with at least a 2-point improvement from baseline among participants with a baseline ss-PGA score \>=3.

    Time frame: Week 16

  11. The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (sPGA 0/1)

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; Severe = 4). sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 or 1 with at least 2-point improvement from baseline using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 24 or who have missing week 24 endpoint data for any reason.

    Time frame: Week 24

  12. The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 75)

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 24 or who have missing week 24 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

    Time frame: Baseline and Week 24

  13. The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 90)

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the response as a number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 24 or who have missing week 24 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

    Time frame: Baseline and Week 24

  14. The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 52 and at Week 24 (sPGA 0/1)

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; Severe = 4). sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 or 1 with at least 2-point improvement from baseline using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 52 or who have missing week 52 endpoint data for any reason.

    Time frame: Week 52 and Week 24

  15. The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 52 and at Week 24 (PASI 75)

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 52, or who have missing week 52 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

    Time frame: Baseline, Week 52 and Week 24

  16. The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 52 and at Week 24 (PASI 90)

    PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the response as a number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 52, or who have missing week 52 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

    Time frame: Baseline, Week 52 and Week 24

07

Results

Posted Jan 30, 2023

Participant flow

Pre-treatment
Participant flow — Pre-treatment
MilestoneBMS-986165PlaceboApremilast
Started332166168
Completed332165168
Not completed010
Withdrew: Participant discontinued from study prior to treatment due to incorrect randomization010
Treatment Week 0 - Week 16
Participant flow — Treatment Week 0 - Week 16
MilestoneBMS-986165PlaceboApremilast
Started332165168
Completed307145145
Not completed252023
Withdrew: Adverse event5710
Withdrew: Death010
Withdrew: Lack of efficacy011
Withdrew: Lost to follow-up724
Withdrew: Protocol violation112
Withdrew: Withdrawal by subject433
Withdrew: Other reasons853
Treatment Week 16 - Week 24
Participant flow — Treatment Week 16 - Week 24
MilestoneBMS-986165PlaceboApremilast
Started4520145
Completed4420141
Not completed1004
Withdrew: Adverse event101
Withdrew: Lack of efficacy300
Withdrew: Lost to follow-up002
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject201
Withdrew: Other reasons300
Treatment Week 24 - Week 52
Participant flow — Treatment Week 24 - Week 52
MilestoneBMS-986165PlaceboApremilast
Started496087
Completed444083
Not completed5204
Withdrew: Adverse event801
Withdrew: Lack of efficacy600
Withdrew: Lost to follow-up501
Withdrew: Protocol violation200
Withdrew: Site terminated by sponsor200
Withdrew: Withdrawal by subject1000
Withdrew: Other reasons1902

Outcome measures

PrimaryThe Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1)

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; Severe = 4). sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 or 1 with at least 2-point improvement from baseline using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1)
ParticipantsBMS-986165Placebo
The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1)17812
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 18.71 · 95% CI 9.51 to 36.81
PrimaryThe Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 75)

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

Time frame:
Baseline and Week 16
Reported as:
Count of participants · Participants
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 75)
ParticipantsBMS-986165Placebo
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 75)19421
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 11.09 · 95% CI 6.49 to 18.95
SecondaryThe Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score at Week 16 (PASI 90)

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the response as a number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

Time frame:
Baseline and Week 16
Reported as:
Count of participants · Participants
The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score at Week 16 (PASI 90)
ParticipantsBMS-986165PlaceboApremilast
The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score at Week 16 (PASI 90)118733
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 16.15 · 95% CI 6.91 to 37.72
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = 0.0002 · Odds ratio (or): 2.40 · 95% CI 1.51 to 3.60
SecondaryThe Number of Participants Who Achieve a 100% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 100)

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the response as a number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

Time frame:
Baseline and Week 16
Reported as:
Count of participants · Participants
The Number of Participants Who Achieve a 100% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 100)
ParticipantsBMS-986165Placebo
The Number of Participants Who Achieve a 100% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 100)471
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 31.30 · 95% CI 4.09 to 239.36
SecondaryThe Number of Participants With a Static Physician's Global Assessment Score of 0 at Week 16 (sPGA 0)

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). sPGA 0 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number of Participants With a Static Physician's Global Assessment Score of 0 at Week 16 (sPGA 0)
ParticipantsBMS-986165PlaceboApremilast
The Number of Participants With a Static Physician's Global Assessment Score of 0 at Week 16 (sPGA 0)5818
Statistical analysis
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.52 · 95% CI 2.07 to 9.84
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 39.54 · 95% CI 5.29 to 295.75
SecondaryChange From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16

PSSD is an 11-item participant-reported instrument that assesses severity of symptoms and participant-observed signs commonly associated in plaque psoriasis. PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participants-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding) using 0-10 numerical ratings. The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). A symptom score will be derived by averaging the 5 questions and multiplying by 10. A sign score will be derived by averaging the 6 questions and multiplying by 10. A total PSSD score with range 0-100 will be derived from taking the average of the symptom and sign scores, where 0 representing the least severe symptom/sign and 100 the most severe. A mBOCF approach will be used for missing data. Baseline is defined as the measurement at the randomization visit (Week 0).

Time frame:
Baseline and Week 16
Reported as:
Mean · Score on a scale
Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16
Score on a scaleBMS-986165Apremilast
Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16-29.4 ± 24.43-22.8 ± 23.40
Statistical analysis
  • BMS-986165 vs Apremilast · ANCOVA · p = <0.0001 · Adjusted mean difference: -8.8 · 95% CI -12.8 to -4.9
SecondaryPsoriasis Symptoms and Signs Diary (PSSD) Symptom Score 0 at Week 16

PSSD with a 24-hour recall period is an 11-item participant-reported instrument that assesses severity of symptoms and participant-observed signs commonly associated in plaque psoriasis. PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participants-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding) using 0-10 numerical ratings. The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). PSSD 0 is the response as a number of participants who experience a PSSD symptom score that is derived from the average of the scores and determines psoriasis severity as 0 among participants with a baseline PSSD symptom score \>= 1.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score 0 at Week 16
ParticipantsBMS-986165PlaceboApremilast
Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score 0 at Week 162417
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = 0.0013 · Odds ratio (or): 13.67 · 95% CI 1.77 to 105.50
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = 0.1702 · Odds ratio (or): 1.84 · 95% CI 0.76 to 4.42
SecondaryThe Number of Participants With a Dermatology Life Quality Index (DLQI) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (DLQI 0/1)

DLQI is a participant-reported quality of life index which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week before questionnaire. Each question is scored on a scale of 0 to 3 by a tick box (0 = "not at all"; 1 = "a little"; 2 = "a lot"; or 3 = "very much"). The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment). DLQI 0/1 is the response as a number of participants who experience DLQI score of 0 or 1 among participants with a baseline DLQI score \>=2.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number of Participants With a Dermatology Life Quality Index (DLQI) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (DLQI 0/1)
ParticipantsBMS-986165Placebo
The Number of Participants With a Dermatology Life Quality Index (DLQI) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (DLQI 0/1)13217
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 6.04 · 95% CI 3.46 to 10.53
SecondaryNumber of Participants With a Physician's Global Assessment-Fingernails (PGA-F) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16

PGA-F overall condition of the fingernails is rated on a 5-point scale (0 = clear; 1 = minimal; 2 = mild; 3 = moderate; and 4 = severe). PGA-F 0/1 is the response as a number of participants with a PGA-F score of 0 or 1 with at least a 2-point improvement from baseline among participants with a baseline PGA-F score \>=3.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Number of Participants With a Physician's Global Assessment-Fingernails (PGA-F) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16
ParticipantsBMS-986165Placebo
Number of Participants With a Physician's Global Assessment-Fingernails (PGA-F) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 1693
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = 0.1049 · Odds ratio (or): 2.84 · 95% CI 0.73 to 10.96
SecondaryThe Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (PASI 75)

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

Time frame:
Baseline and Week 16
Reported as:
Count of participants · Participants
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (PASI 75)
ParticipantsBMS-986165Apremilast
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (PASI 75)19459
Statistical analysis
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.64 · 95% CI 1.78 to 3.91
SecondaryThe Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (sPGA 0/1)

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; Severe = 4). sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 or 1 with at least 2-point improvement from baseline using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (sPGA 0/1)
ParticipantsBMS-986165Apremilast
The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (sPGA 0/1)17854
Statistical analysis
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.53 · 95% CI 1.70 to 3.78
SecondaryThe Number of Participants With a Scalp Specific Physician's Global Assessment (Ss-PGA) Score 0 or 1 at Week 16 (Ss-PGA 0/1)

ss-PGA is a 5-point scale that evaluates scalp lesions in terms of clinical signs of redness, thickness, and scaliness. The higher ss-PGA score denotes to more severe disease activity (0 = absence of disease; 1 = very mild disease; 2 = mild disease; 3 = moderate disease; 4 = severe disease). ss-PGA 0/1 is the response as a number of participants who experience a ss-PGA score that determines scalp lesions severity as 0 or 1 with at least a 2-point improvement from baseline among participants with a baseline ss-PGA score \>=3.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number of Participants With a Scalp Specific Physician's Global Assessment (Ss-PGA) Score 0 or 1 at Week 16 (Ss-PGA 0/1)
ParticipantsBMS-986165PlaceboApremilast
The Number of Participants With a Scalp Specific Physician's Global Assessment (Ss-PGA) Score 0 or 1 at Week 16 (Ss-PGA 0/1)1472143
Statistical analysis
  • BMS-986165 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 11.92 · 95% CI 6.69 to 21.25
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.65 · 95% CI 2.21 to 6.04
SecondaryThe Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (sPGA 0/1)

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; Severe = 4). sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 or 1 with at least 2-point improvement from baseline using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 24 or who have missing week 24 endpoint data for any reason.

Time frame:
Week 24
Reported as:
Count of participants · Participants
The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (sPGA 0/1)
ParticipantsBMS-986165Apremilast
The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (sPGA 0/1)19552
Statistical analysis
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.23 · 95% CI 2.16 to 4.83
SecondaryThe Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 75)

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 24 or who have missing week 24 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

Time frame:
Baseline and Week 24
Reported as:
Count of participants · Participants
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 75)
ParticipantsBMS-986165Apremilast
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 75)23064
Statistical analysis
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.76 · 95% CI 2.53 to 5.60
SecondaryThe Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 90)

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the response as a number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 24 or who have missing week 24 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

Time frame:
Baseline and Week 24
Reported as:
Count of participants · Participants
The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 90)
ParticipantsBMS-986165Apremilast
The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 90)14037
Statistical analysis
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.63 · 95% CI 1.71 to 4.05
SecondaryThe Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 52 and at Week 24 (sPGA 0/1)

The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; Severe = 4). sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 or 1 with at least 2-point improvement from baseline using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 52 or who have missing week 52 endpoint data for any reason.

Time frame:
Week 52 and Week 24
Reported as:
Count of participants · Participants
The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 52 and at Week 24 (sPGA 0/1)
ParticipantsBMS-986165Apremilast
The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 52 and at Week 24 (sPGA 0/1)15137
Statistical analysis
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.03 · 95% CI 1.96 to 4.69
SecondaryThe Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 52 and at Week 24 (PASI 75)

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 52, or who have missing week 52 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

Time frame:
Baseline, Week 52 and Week 24
Reported as:
Count of participants · Participants
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 52 and at Week 24 (PASI 75)
ParticipantsBMS-986165Apremilast
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 52 and at Week 24 (PASI 75)18751
Statistical analysis
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.11 · 95% CI 2.06 to 4.69
SecondaryThe Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 52 and at Week 24 (PASI 90)

PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the response as a number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 52, or who have missing week 52 endpoint data for any reason. Baseline is defined as the measurement at the randomization visit (Week 0).

Time frame:
Baseline, Week 52 and Week 24
Reported as:
Count of participants · Participants
The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 52 and at Week 24 (PASI 90)
ParticipantsBMS-986165Apremilast
The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 52 and at Week 24 (PASI 90)10326
Statistical analysis
  • BMS-986165 vs Apremilast · Cochran-Mantel-Haenszel · p = 0.0002 · Odds ratio (or): 2.55 · 95% CI 1.55 to 4.19

Adverse events

Collected over Participants were assessed for All-cause mortality from their first dose to study completion (up to approximately 24 months). SAEs and Other AEs were assessed from first dose to 30 days following last dose (up to approximately 12 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BMS-986165 Week 0 up to Week 160/332 (0%)7/332 (2.1%)76/332 (22.9%)
Placebo Week 0 up to Week 161/166 (0.6%)9/165 (5.5%)24/165 (14.5%)
Apremilast Week 0 up to Week 160/168 (0%)4/168 (2.4%)60/168 (35.7%)
BMS-986165 Week 0 up to Week 520/531 (0%)31/531 (5.8%)197/531 (37.1%)
Placebo Week 0 up to Week 521/166 (0.6%)9/165 (5.5%)24/165 (14.5%)
Apremilast Week 0 up to Week 520/168 (0%)6/168 (3.6%)80/168 (47.6%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventBMS-986165 Week 0 up to Week 16Placebo Week 0 up to Week 16Apremilast Week 0 up to Week 16BMS-986165 Week 0 up to Week 52Placebo Week 0 up to Week 52Apremilast Week 0 up to Week 52
Acute myocardial infarctionCardiac disorders0/3321/1650/1680/5311/1650/168
Angina unstableCardiac disorders0/3321/1650/1681/5311/1650/168
Hypertensive heart diseaseCardiac disorders0/3321/1650/1680/5311/1650/168
Enterocutaneous fistulaGastrointestinal disorders0/3321/1650/1680/5311/1650/168
Intra-abdominal fluid collectionGastrointestinal disorders0/3321/1650/1680/5311/1650/168
Small intestinal perforationGastrointestinal disorders0/3321/1650/1680/5311/1650/168
Hernia perforationGeneral disorders0/3321/1650/1680/5311/1650/168
Incarcerated herniaGeneral disorders0/3321/1650/1680/5311/1650/168
DiverticulitisInfections and infestations0/3321/1650/1680/5311/1650/168
Fracture displacementInjury, poisoning and procedural complications0/3321/1650/1680/5311/1650/168
Most frequent other events
Most frequent other events
EventBMS-986165 Week 0 up to Week 16Placebo Week 0 up to Week 16Apremilast Week 0 up to Week 16BMS-986165 Week 0 up to Week 52Placebo Week 0 up to Week 52Apremilast Week 0 up to Week 52
NasopharyngitisInfections and infestations21/3327/16514/16896/5317/16526/168
HeadacheNervous system disorders16/3325/16517/16835/5315/16523/168
NauseaGastrointestinal disorders7/3324/16519/1687/5314/16521/168
DiarrhoeaGastrointestinal disorders13/3326/16517/16830/5316/16519/168
Upper respiratory tract infectionInfections and infestations21/3326/1653/16850/5316/1656/168
HypertensionVascular disorders6/3320/1656/16814/5310/1659/168

Baseline characteristics

Age, Continuous
Age, Continuous(Years)BMS-986165PlaceboApremilastTotal
Mean45.9 ± 13.7147.9 ± 13.9844.7 ± 12.0646.1 ± 13.41
Sex: Female, Male
Sex: Female, Male(Participants)BMS-986165PlaceboApremilastTotal
Female1025358213
Male230113110453
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BMS-986165PlaceboApremilastTotal
Hispanic or Latino502630106
Not Hispanic or Latino282140138560
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BMS-986165PlaceboApremilastTotal
White267128139534
Black or African American2316
Asian593428121
American Indian or Alaska Native0000
Native Hawaiian or other Pacific Islander0000
Other4105
08

Study locations

165 sites
  • Achieve Clinical Research
    Birmingham, Alabama 35216, United States
  • Coastal Clinical Research - Mobile
    Mobile, Alabama 36608, United States
  • Elite Clinical Studies
    Phoenix, Arizona 85018, United States
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • Synexus - Tucson
    Tucson, Arizona 85741, United States
  • Hull Dermatology
    Rogers, Arkansas 72758, United States
  • First OC Dermatology & Belle-Aimee Skincare Clinic Fountain Valley
    Fountain Valley, California 92708, United States
  • University California at Irvine Dermatology Clinical Research Center
    Irvine, California 92697, United States
  • Keck School of Medicine
    Los Angeles, California 90033, United States
  • Dream Team Clinical Research
    Pomona, California 91767, United States
  • University Dermatology Group
    San Diego, California 92123, United States
  • Unison Clinical Trials
    Sherman Oaks, California 91403, United States
  • New England Research Associates
    Bridgeport, Connecticut 06606, United States
  • Precision Clinical Research
    Davie, Florida 33328, United States
  • Indago Research and Health Center
    Hialeah, Florida 33012, United States
  • San Marcus Research Clinic
    Miami Lakes, Florida 33014, United States
  • LCC Medical Research
    Miami, Florida 33126, United States
  • International Dermatology Research
    Miami, Florida 33144, United States
  • Well Pharma Medical Research
    Miami, Florida 33173, United States
  • Miami Dade Medical Research Institute
    Miami, Florida 33176, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Ameriderm Research
    Ormond Beach, Florida 32174, United States
  • Olympian Clinical Research
    Tampa, Florida 33614-7118, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409-3401, United States
  • Hamilton Dermatology
    Alpharetta, Georgia 30022, United States
  • Healthcare Research Network - Flossmoor
    Flossmoor, Illinois 60402, United States
  • Springfield Clinic
    Springfield, Illinois 62703, United States
  • Deaconess Clinic Downtown
    Evansville, Indiana 47708, United States
  • The Dermatology Center
    New Albany, Indiana 47150, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • The South Bend Clinic
    South Bend, Indiana 46617, United States
  • Kansas City Dermatology
    Overland Park, Kansas 66215, United States
  • Dermatology Specialists Research-Kentucky
    Louisville, Kentucky 40241, United States
  • Clinical Trials of America - Monroe
    Monroe, Louisiana 71201, United States
  • Etre Cosmetic Dermatology and Laser Center
    New Orleans, Louisiana 70130, United States
  • ActivMed Practices and Research - Beverly
    Beverly, Massachusetts 01915, United States
  • DermCare Experts
    Quincy, Massachusetts 02169, United States
  • David Fivenson MD Dermatology
    Ann Arbor, Michigan 48103, United States
  • Somerset Skin Centre
    Troy, Michigan 48084, United States
  • Associated Skin Care Specialists - Minnesota Clinical Study Center
    New Brighton, Minnesota 55112, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Forest Hills Dermatology Group
    Kew Gardens, New York 11374, United States
  • Mount Sinai - Queens
    New York, New York 10023, United States
  • PMG Research of Charlotte
    Charlotte, North Carolina 28209, United States
  • Duke University Health System - Duke Clinic
    Durham, North Carolina 27710-4000, United States
  • M3 Wake Research, Inc.
    Raleigh, North Carolina 27612, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43203, United States
  • Synexus - Columbus
    Columbus, Ohio 43212, United States
  • Health Research of Oklahoma
    Oklahoma City, Oklahoma 73103-2433, United States
  • Oregon Medical Research Center
    Portland, Oregon 97223-6683, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Clinical Research Center of Reading
    Wyomissing, Pennsylvania 19610, United States
  • Synexus Clinical Research - Anderson
    Anderson, South Carolina 29621, United States
  • Clinical Research Center of the Carolinas
    Charleston, South Carolina 29407, United States
  • Interspond - Stones River Dermatology - Murfreesboro Office
    Murfreesboro, Tennessee 37129, United States
  • Westlake Dermatology - Westlake
    Austin, Texas 78746, United States
  • Dermatology Treatment and Research Center
    Dallas, Texas 75230, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
  • Menter Dermatology Research Institute
    Dallas, Texas 75246, United States
  • Austin Institute for Clinical Research - Pflugerville
    Pflugerville, Texas 78660, United States
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78218, United States
  • Interspond - Acclaim Dermatology
    Sugar Land, Texas 77479, United States
  • Center for Clinical Studies - Webster
    Webster, Texas 77598, United States
  • Dermatology Associates of Seattle
    Seattle, Washington 98101, United States
  • Eastern Washington Dermatology
    Walla Walla, Washington 99362, United States
  • Kirk Barber Research
    Calgary, Alberta T2G 1B1, Canada
  • Dr. Chih-ho Hong Medical Inc.
    Surrey, British Columbia V3R 6A7, Canada
  • Wiseman Dermatology Research
    Winnipeg, Manitoba R3M 3Z4, Canada
  • The Guenther Dermatology Research Centre
    London, Ontario N6A 3H7, Canada
  • Office of Dr. Arnon Moshe Katz
    Newmarket, Ontario L3Y 6P5, Canada
  • North Bay Dermatology Centre
    North Bay, Ontario P1B 3Z7, Canada
  • Institute of Cosmetic and Laser Surgery
    Oakville, Ontario L6J 7W5, Canada
  • Skin Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • The Centre for Dermatology - Richmond Hill
    Richmond Hill, Ontario L4B 1A5, Canada
  • XLR8 Medical Research
    Windsor, Ontario N8W 1E6, Canada
  • Docteur David Gratton Dermatologue
    Montreal, Quebec H3H 1V4, Canada
  • Siena Medical Research
    Montreal, Quebec H3Z 2S6, Canada
  • Centre de Recherche Dermatologique du Quebec Metropolitain
    Quebec, G1V 4X7, Canada
  • Local Institution
    Beijing, Beijing 100050, China
  • Local Institution
    Wuhan, Hubei 430030, China
  • Local Institution
    Hangzhou, Zhejiang 310009, China
  • Charite Universitatsmedizin Berlin
    Berlin, 10117, Germany
  • Klinische Forschung Dresden GmbH
    Dresden, 01069, Germany
  • Local Institution - 0165
    Nagoya, Aichi 467-8602, Japan
  • Local Institution - 0181
    Toon-Shi, Ehime 7910295, Japan
  • Fukuoka University Hospital
    Fukuoka-shi, Fukuoka 814-0180, Japan
  • University of Occupational and Environmental Health, Japan
    Kitakyushu, Fukuoka 807-8555, Japan
  • Sapporo Skin Clinic
    Sapporo, Hokkaido 060-0063, Japan
  • Kobe University Hospital
    Kobe, Hyogo 650-0017, Japan
  • Local Institution - 0182
    Isehara City, Kanagawa 259-1193, Japan
  • National Hospital Organization Yokohama Medical Center
    Yokohama-shi, Kanagawa 2458575, Japan
  • Local Institution - 0169
    Yokohama, Kanagawa 236-0004, Japan
  • Kochi Medical School Hospital
    Nakoku, Kochi 783-8505, Japan
  • University Hospital - Kyoto Preferctural University of Medicine
    Kyoto-city, Kyoto 602-8566, Japan
  • Mie University Hospital
    Tsu, MIE 514-8507, Japan
  • Local Institution - 0166
    Matsumoto, Nagano 3908621, Japan
  • Kurashiki Central Hospital
    Kurashiki, Okayama 7108602, Japan
  • Hamamatsu University Hospital
    Hamamatsu, Shizuoka 431-3192, Japan

Showing the first 100 of 165 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Sep 2020, 24 months.

Results were first posted in Jan 2023, 2 years 4 months after primary completion. A results delay was requested in Sep 2021.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 24 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2018
First posted
Aug 9, 2018
StartActual
Aug 7, 2018
Primary completionActual
Sep 2, 2020
CompletionActual
Sep 2, 2020
Results delay requested
Sep 1, 2021
Results first posted
Jan 30, 2023
Last update
Jan 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03624127
Responsible party
Sponsor
First posted
Aug 9, 2018
Start date
Aug 7, 2018
Primary completion
Sep 2, 2020
Completion
Sep 2, 2020
Results posted
Jan 30, 2023
Last update
Jan 30, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion